IMPACT OF TIME TO RELAPSE AND RESPONSE TO SALVAGE THERAPY ON POST AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Aung M Tun,Yucai Wang,Seth M. Maliske,Umar Farooq,Ivana N. Micallef,David J. Inwards,Luis F. Porrata,Stephen M. Ansell,Allison C. Rosenthal,Mohamed A. Kharfan-Dabaja,Brian K. Link,Jose C. Villasboas,Jonas Paludo,James R. Cerhan,Thomas M. Habermann,Thomas E. Witzig,Grzegorz S. Nowakowski,Patrick B. Johnston

IMPACT OF TIME TO RELAPSE AND RESPONSE TO SALVAGE THERAPY ON POST AUTOLOGOUS STEM CELL TRANSPLANT OUTCOMES IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

2021

Aung M Tun
Yucai Wang
Seth M. Maliske
Umar Farooq
Ivana N. Micallef
David J. Inwards
Luis F. Porrata
Stephen M. Ansell
Allison C. Rosenthal
Mohamed A. Kharfan-Dabaja
Brian K. Link
Jose C. Villasboas
Jonas Paludo
James R. Cerhan
Thomas M. Habermann
Thomas E. Witzig
Grzegorz S. Nowakowski
Patrick B. Johnston

e19501Background: The current standard of care for patients with relapsed or refractory (RR) diffuse large B-cell lymphoma (DLBCL) following frontline immunochemotherapy (IC) is salvage therapy, fo...

Keywords:

Internal medicine
Salvage therapy
Lymphoma
time to relapse
Refractory Diffuse Large B-Cell Lymphoma
standard of care
Refractory
Medicine
Stem cell
Oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations